MetaCap

Longeveron (LGVN) vs Exicure (XCUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Exicure is the larger company by market cap ($5.9 million vs $5.6 million), about 1.1 times the size, while Longeveron is growing revenue faster (-49.9% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LGVN-31.97%XCUR-11.75%
+39%-4%-47%
Oct 7, 20261 yearNov 20, 2026
LGVN-33.06%XCUR-14.28%
+9%-19%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LGVN versus XCUR key metrics
MetricLGVNXCUR
Share price$1.66$0.9001
Market cap$5.60M$5.89M
1-day change-8.79%-12.82%
EPS (TTM)$-7.95$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.20M$0
Revenue growth (YoY)-49.87%-100.00%
Net income (latest FY)$-22.70M$-4.95M
Gross margin66.97%—
Operating margin-1942.20%—
Net margin-1893.58%—
52-week high$12.30$9.48
52-week low$1.31$0.777
Distance from 52-week high-86.50%-90.51%
Analyst consensusnone—
Avg. price target upside+3589.76%—
Average volume115.35K53.56K
Shares outstanding3.23M6.55M
Employees381
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Longeveron grew revenue faster in its latest fiscal year (-49.87% vs -100.00%).

About Longeveron

LGVN stock →

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Exicure

XCUR stock →

Exicure, Inc. does not have significant operations.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

LGVN vs XCUR FAQ

Which is bigger, Longeveron or Exicure?

Exicure (XCUR) is larger, with a market capitalization of $5.89M compared with $5.60M for Longeveron (LGVN).

Are Longeveron and Exicure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons